ONCOZ.ST
Price:
$6.03
Market Cap:
$71.72M
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Industry
Biotechnology
IPO Date
2021-02-12
Stock Exchange
STO
Ticker
ONCOZ.ST
According to OncoZenge AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -8.37. This represents a change of -108.87% compared to the average of 94.40 of the last 4 quarters.
The mean historical PE Ratio of OncoZenge AB (publ) over the last ten years is -64.70. The current -8.37 PE Ratio has changed 1.19% with respect to the historical average. Over the past ten years (40 quarters), ONCOZ.ST's PE Ratio was at its highest in in the March 2025 quarter at 395.32. The PE Ratio was at its lowest in in the September 2021 quarter at -42.58.
Average
-64.70
Median
-5.06
Minimum
-279.94
Maximum
-1.38
Discovering the peaks and valleys of OncoZenge AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 122.13%
Maximum Annual PE Ratio = -1.38
Minimum Annual Increase = -96.04%
Minimum Annual PE Ratio = -279.94
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -5.06 | 122.13% |
| 2023 | -2.28 | 64.80% |
| 2022 | -1.38 | -96.04% |
| 2021 | -34.84 | -87.55% |
The current PE Ratio of OncoZenge AB (publ) (ONCOZ.ST) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.90
5-year avg
-64.70
10-year avg
-64.70
OncoZenge AB (publ)’s PE Ratio is less than AcouSort AB (publ) (-4.05), less than Lipigon Pharmaceuticals AB (publ) (-0.20), less than Simris Alg AB (publ) (-1.84), less than Newbury Pharmaceuticals AB (publ) (-3.32), less than Spago Nanomedical AB (publ) (-1.94), less than ExpreS2ion Biotech Holding AB (publ) (-0.96), less than Alligator Bioscience AB (publ) (-0.19), less than Sprint Bioscience AB (publ) (-6.27), less than Ortivus AB (publ) (-2.33), greater than ScandiDos AB (publ) (-48.71),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.05 | $57.35M | |
| -0.20 | $7.27M | |
| -1.84 | $53.89M | |
| -3.32 | $39.27M | |
| -1.94 | $39.58M | |
| -0.96 | $43.86M | |
| -0.19 | $15.15M | |
| -6.27 | $160.91M | |
| -2.33 | $53.84M | |
| -48.71 | $61.29M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like OncoZenge AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like OncoZenge AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is OncoZenge AB (publ)'s PE Ratio?
How is the PE Ratio calculated for OncoZenge AB (publ) (ONCOZ.ST)?
What is the highest PE Ratio for OncoZenge AB (publ) (ONCOZ.ST)?
What is the 3-year average PE Ratio for OncoZenge AB (publ) (ONCOZ.ST)?
What is the 5-year average PE Ratio for OncoZenge AB (publ) (ONCOZ.ST)?
How does the current PE Ratio for OncoZenge AB (publ) (ONCOZ.ST) compare to its historical average?